Arizona Neuroscience Research, LLC

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis5 trials
• Alzheimer disease1 trial
• Dystonia1 trial
• Essential tremor1 trial
• Myasthenia gravis1 trial

Phase

• Phase 34 trials
• Phase 23 trials
• Phase 42 trials

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting2 trials
• Terminated2 trials

Lead sponsor

• Novartis Pharmaceuticals2 trials
• Cassava Sciences, Inc.1 trial
• Hoffmann-La Roche1 trial
• Janssen Research & Development, LLC1 trial
• Jazz Pharmaceuticals1 trial
• and 3 more

Running trials

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

  Contact: Leslie Zuniga (principal investigator)

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

  NCT05090371· Phase 4· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting

Closed trials

• Terminated

  Study of the Oral Treatment MTR-601 in Cervical Dystonia

  NCT06830642· Phase 2· Motric Bio· Source

• Completed

  Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

  NCT06083753· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

  NCT05084638· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

  NCT05122650· Phase 2· Jazz Pharmaceuticals· Source

• Terminated

  Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT05026177· Phase 3· Cassava Sciences, Inc.· Source